On-Demand Webinars
Conversations on Biopharma Commercialization
Industry thought leaders with extensive and diverse backgrounds provide commercialization insights, perspectives, and guidance.
Why Start Early? Let's Count The Reasons!
Early Commercialization Planning Is Vital for Maximizing Both the Value of Your Company and Your Asset
What does commercialization planning entail?
- Preparing the market and the company to successfully deliver their product to the patients.
- A complex, multi-year process that should start early in the clinical development program through preparation for launch and beyond.
- Cross-functional integration, including the incorporation of market, customer, and patient insights throughout the journey.
- And much more!
To access the on-demand webinar, click here.
Leveraging Technology to Accelerate Biopharma Commercialization Planning
It's About Time (and Money)
Hear Sue Nemetz and the Corval team as they discuss the role of technology in creating a paradigm shift in biopharma commercialization planning.
The dynamic financial environment brings increased pressures and magnifies familiar pain points for emerging companies, elevating the need for a new approach to help teams get a fast, efficient, and early start on commercialization planning.
To access the on-demand webinar, click here.
Biopharma Survival in Uncertain Times
Expert perspectives on Maintaining Resilience
Uncertainty Is the One Certainty
Hear industry thought leaders discuss the unique challenges facing biotech/biopharma in today’s unsettled market—with a special focus on commercialization planning and potential solutions that enable high impact but conserve resources.
To access the on-demand webinar and key takeaways document, click here.
Rare Diseases
Shaping Biopharma's Future from the Past
Watch this Genzyme-veteran panel for an insightful and provocative discussion on what mistakes to avoid, what to get right early, and how to stand out from the ever-growing pack of competitors in rare disease drug development.
What essential lessons have we learned, and what questions are we asking ourselves?
- Will changes in the capital markets hamstring rare disease development?
- Is the patient still coming first?
- Has the macro environment changed how we advise companies?
To access the on-demand webinar and key takeaways document, click here.
Questions About Corval?
Reach out today to learn how to get an early start on commercialization planning with Corval and set your asset up for long-term success.
We’re committed to your privacy. For more information, please see our Privacy Policy and Terms and Conditions.